Honeysuckle-Derived Nanovesicles Regulate Gut Microbiota for the Treatment of Inflammatory Bowel Disease.

ABSTRACT: Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's disease, significantly impairs patients' quality of life and is characterized by a compromised intestinal barrier, pathogenic bacterial colonization, and chronic inflammation. The gut microbiota has emerged as a therapeutic target for IBD owing to its role in modulating immune responses, metabolic pathways, and barrier function. In this study, the therapeutic potential of honeysuckle-derived nanovesicles (HNVs) in a dextran sodium sulfate-induced murine model of UC is investigated. Oral administration of HNVs alleviates colitis symptoms, reduces colonic inflammation and histopathological damage, restores Treg/Th17 balance, and repairs intestinal barrier integrity. These effects are associated with favorabl

SUBMITTER: Wang Y 

PROVIDER: S-EPMC12677632 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature